Nuvation Bio Inc (NYSE: NUVB)’s stock price has gone rise by 21.81 in comparison to its previous close of 1.88, however, the company has experienced a 25.82% increase in its stock price over the last five trading days. businesswire.com reported 2025-03-06 that NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “Nuvation Bio had a transformative year in 2024, marked by significant milestones. We acquired AnHeart Therapeutics, reported positive pivotal data for taletrectinib, and submitted the NDA for taletrectinib, which was accep.
Is It Worth Investing in Nuvation Bio Inc (NYSE: NUVB) Right Now?
Moreover, the 36-month beta value for NUVB is 1.44. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NUVB is 226.82M and currently, short sellers hold a 11.54% of that float. On March 12, 2025, NUVB’s average trading volume was 2.49M shares.
NUVB’s Market Performance
NUVB stock saw a decrease of 25.82% in the past week, with a monthly decline of -3.78% and a quarterly a decrease of -17.33%. The volatility ratio for the week is 13.80%, and the volatility levels for the last 30 days are 8.42% for Nuvation Bio Inc (NUVB). The simple moving average for the last 20 days is 9.54% for NUVB’s stock, with a simple moving average of -16.06% for the last 200 days.
Analysts’ Opinion of NUVB
Many brokerage firms have already submitted their reports for NUVB stocks, with Jefferies repeating the rating for NUVB by listing it as a “Buy.” The predicted price for NUVB in the upcoming period, according to Jefferies is $10 based on the research report published on March 27, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NUVB reach a price target of $5. The rating they have provided for NUVB stocks is “Buy” according to the report published on March 26th, 2024.
Jefferies gave a rating of “Hold” to NUVB, setting the target price at $2 in the report published on January 06th of the previous year.
NUVB Trading at -4.38% from the 50-Day Moving Average
After a stumble in the market that brought NUVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.95% of loss for the given period.
Volatility was left at 8.42%, however, over the last 30 days, the volatility rate increased by 13.80%, as shares surge +0.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.79% lower at present.
During the last 5 trading sessions, NUVB rose by +25.82%, which changed the moving average for the period of 200-days by -32.65% in comparison to the 20-day moving average, which settled at $2.0900. In addition, Nuvation Bio Inc saw -13.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NUVB starting from Wang Junyuan Jerry, who sale 56,361 shares at the price of $2.89 back on Nov 11 ’24. After this action, Wang Junyuan Jerry now owns 3,866,228 shares of Nuvation Bio Inc, valued at $162,883 using the latest closing price.
Mashal Robert, the Director of Nuvation Bio Inc, purchase 100,000 shares at $2.20 during a trade that took place back on Oct 08 ’24, which means that Mashal Robert is holding 100,000 shares at $220,000 based on the most recent closing price.
Stock Fundamentals for NUVB
Current profitability levels for the company are sitting at:
- -21.28 for the present operating margin
- 0.06 for the gross margin
The net margin for Nuvation Bio Inc stands at -72.14. The total capital return value is set at -0.35. Equity return is now at value -106.27, with -97.74 for asset returns.
Based on Nuvation Bio Inc (NUVB), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -14.63. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -491.37.
Currently, EBITDA for the company is -566.91 million with net debt to EBITDA at 0.05. When we switch over and look at the enterprise to sales, we see a ratio of 94.81. The receivables turnover for the company is 0.48for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.04.
Conclusion
To wrap up, the performance of Nuvation Bio Inc (NUVB) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
